- Title: Subtitle
- Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
- Creators
- Amitkumar Mehta - University of Alabama at BirminghamUmar Farooq - University of IowaAndy Chen - University of PortlandJoseph P. McGuirk - University of Kansas Medical CenterThomas Ly - Fate Therapeutics (United States)Lilly Wong - Fate Therapeutics (United States)Sarah Cooley - Fate Therapeutics (United States)Bahram Valamehr - Fate Therapeutics (United States)Rebecca Elstrom - Fate Therapeutics (United States)Yu-Waye Chu - Fate Therapeutics (United States)Jae H. Park - Kettering University
- Resource Type
- Abstract
- Publication Details
- Blood, Vol.140(Supplement 1), pp.4577-4578
- DOI
- 10.1182/blood-2022-167194
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
- Date published
- 11/15/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984362755602771
Abstract
Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
Blood, Vol.140(Supplement 1), pp.4577-4578
11/15/2022
DOI: 10.1182/blood-2022-167194
Details
Metrics
117 Record Views